Q2 FY2026 EarningsQ2 FY26 results beat consensus across all key metrics: revenue $920.6M vs. $906.4M expected, and adjusted diluted EPS $2.32 vs. $2.11 expected. Health & Science Technologies (HST) drove growth with 12% organic sales increase, fueled by AI-driven data center demand. Full-year organic growth guidance was raised to 5-6% (up from 3-4%), and adjusted EPS guidance was increased to $8.70 - $8.85, significantly above the prior midpoint.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Idex(IEX) the Revenue is 920.6 M (+6.38%), Beat estimate;the EBIT is 202.7 M (+7.48%), Beat estimate;the EPS is 1.93 (+10.92%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.92B6.38%
0.91B4.74%
+0.01B1.64%
EBITExceed expectations
0.20B7.48%
0.19B0.54%
+0.01B6.94%
EPSExceed expectations
1.9310.92%
1.76291.31%
+0.16719.61%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf